You are here

Vigabatrin Approved for Adult and Pediatric Epileptic Seizures

Adjunctive Therapy is First Generic Version of Sabril for Focal Seizures

The FDA has approved vigabatrin 500 mg tablets (Teva Pharmaceuticals USA) as an adjunctive therapy for complex partial seizures. The drug is indicated for treating focal seizures in patients aged 10 years and older who have responded inadequately to several alternative treatments.

Complex partial seizures begin in a specific part of the brain and can affect consciousness. They typically last between 30 and 90 seconds, and are often followed by disorientation, confusion, and/or fatigue.

Vigabatrin’s most common side effects include dizziness, fatigue, somnolence, involuntary eye movement, tremor, blurred vision, memory impairment, weight gain, arthralgia, upper respiratory tract infection, aggression, diplopia, abnormal coordination, and a confused state. Serious side effects include permanent vision loss and risk of suicidal thoughts or actions.

Source: PR Newswire, January 16, 2019

Recent Headlines

U.S., Australia, and Canada Approve Endometrial Cancer Regimen
Single daily pill combines hypertension, cholesterol drugs
Drug With Androgen Deprivation Therapy Cut Risk of Death by 33% Compared With Placebo + ADT
A Diabetes Drug For People Without Diabetes
Roche Drug Outperformed Standard of Care in Phase 2 Study
One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs